Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
AZO heads into the final stretch before its December earnings with a quiet but persistent build in short interest, a Street that stayed bullish after a messy quarter, and options markets that have turned noticeably more defensive over the past month.
The most telling shift over the past few weeks is in how analysts responded to the fiscal Q4 report. When results landed in late September, the reaction was broad and unanimous in one direction: nearly every firm on the name trimmed its price target. JP Morgan cut to $3,700 from $3,850. Raymond James dropped to $3,700 from $4,000. BMO Capital took its target down to $3,500 from $4,000. Barclays moved to $3,400 from $3,637. Bernstein, meanwhile, initiated coverage at Outperform with a $3,698 target, walking straight into the reset. What is notable is that not one firm changed its rating. Eighteen analysts carry a buy or equivalent. The consensus read is that Q4 stumbled, not that the thesis broke. The mean target at $3,720 implies roughly 28% upside from the current $2,893, a gap wide enough to show the Street's conviction but also to reflect how far the stock has fallen from where analysts originally set their sights.
The bull case rests on the commercial business holding up. DIFM comps ran near 6%, and Mega Hub expansion gives the company a durable growth engine that does not depend on the DIY consumer recovering quickly. Bears point to the other side of the same ledger: domestic comps of 1.6% missed expectations, DIY traffic was negative, and Q4 revenue of $6.59 billion fell short of estimates. Tariff exposure, wage pressure, and SG&A growth all sit in the risk column for fiscal 2027. The EV/EBITDA multiple has drifted up modestly over the past 30 days to 11.8x, while the P/E at 15.4x remains reasonable for a name of this quality, though the deeply negative price-to-book (a structural artefact of AutoZone's aggressive buyback program) makes simple comparisons unreliable.
Short interest has climbed sharply over the past month, up 29% in shares, though the absolute level stays modest at 3.1% of the free float. That 30-day build matters more for what it signals about marginal conviction than for any squeeze mechanics. The borrow market is completely loose: availability is nearly 6,400%, meaning the lending pool dwarfs the current short position by a wide margin. Cost to borrow has eased to 0.34%, down from around 0.55% in late September. Short sellers can get in and out cheaply, which is consistent with tactical positioning rather than a committed short thesis. The ORTEX short score at 33 sits in the lower half of its range, with no meaningful directional signal over the past two weeks.
Options markets tell a somewhat different story. The put/call ratio at 0.99 is running above its 20-day average of 0.98, but the gap is narrow and the z-score barely registers at 0.07. The more interesting observation is the directional shift over the past six weeks. Through mid-September, the PCR was consistently in the low 0.87 to 0.88 range. Since late September it has traded in a band from 0.98 to 1.02. That is not panic hedging, but it is a clear step-up in the weight of put volume relative to calls, matching the mood of a market that has absorbed a miss and is reassessing its optimism without abandoning the position.
The closest peer, ORLY, gained 1% on the week while AZO lost a fifth of a percent. HD and LOW both added more than 2.5% over the same period, suggesting AZO is carrying more company-specific weight than the broader retail group.
With the next print 62 days out on December 15, the question for the coming weeks is whether the commercial momentum that bulls are counting on shows up in any real-economy signals, and whether the step-up in put volume fades as the stock stabilises or deepens if the consumer picture deteriorates further.
See the live data behind this article on ORTEX.
Open AZO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
